Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia
NCT01940198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117
Last updated 2013-09-12
Summary
This observational study will aim to determine long-term atazanavir experience in a high HIV caseload primary care practice in Sydney, Australia.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
Holdsworth House Medical Practice
lead OTHER
Principal Investigators
-
Mark Bloch, Dr. · Holdsworth House Medical Practice
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-30
- Primary Completion
- 2011-08-31
- Completion
- 2012-09-30
Countries
- Australia
Study Locations
More Related Trials
-
Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)
NCT01159223 ·Status: COMPLETED ·Phase: PHASE4
-
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
NCT01837719 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen
NCT00135447 ·Status: COMPLETED
-
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
NCT01605084 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
NCT00002045 ·Status: COMPLETED ·Phase: NA
-
Comparative Tolerability of Protease Inhibitors
NCT01450618 ·Status: COMPLETED
-
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
NCT00357188 ·Status: COMPLETED ·Phase: PHASE1
-
Raltegravir and Atazanavir Dosing Strategy Study
NCT00874523 ·Status: COMPLETED ·Phase: PHASE3
-
SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat
NCT02589158 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
NCT00135395 ·Status: COMPLETED ·Phase: PHASE3
-
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
NCT00120393 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz
NCT01458769 ·Status: COMPLETED ·Phase: PHASE1
-
Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
NCT02034838 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
NCT00435929 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
NCT00326716 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
NCT02473328 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
NCT01620944 ·Status: TERMINATED ·Phase: PHASE3
-
Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
NCT00096746 ·Status: COMPLETED
-
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study
NCT01073761 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
NCT01511809 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients
NCT00355719 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics of Atazanavir in Special Populations
NCT03923231 ·Status: COMPLETED
-
A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
NCT02542852 ·Status: COMPLETED ·Phase: PHASE2
-
Phase IIB Pilot of Atazanavir + Raltegravir
NCT00768989 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
NCT01105611 ·Status: UNKNOWN ·Phase: PHASE4